The correlation between serum asprosin and left ventricular diastolic dysfunction in elderly patients with type 2 diabetes mellitus in the community

Abstract

ABSTRACT Aims/Introduction Serum asprosin is expected to become a screening indicator in early‐stage diabetic heart disease. The relationship between serum asprosin and left ventricular diastolic dysfunction (LVDD) was studied in elderly patients with type 2 diabetes mellitus in the community. Materials and Methods A total of 252 elderly patients with type 2 diabetes mellitus were recruited from Zhuoma Community Care Station and Chengbei West Street Community Care Service Center in Changzhi City of Shanxi Province from November 2019 to July 2021. Patients were divided into the LVDD group (n = 195) and the non‐LVDD group (n = 57). The t‐test, Mann–Whitney U test, and χ2 test were used to compare indicators between the LVDD group and the non‐LVDD group. Pearson or Spearman correlation analysis was adopted to evaluate the correlation between serum asprosin and other clinical data. Multivariate logistic regression analysis was applied to analyze the influencing factors on LVDD. Results Compared with patients without LVDD, patients with LVDD had a higher level of low‐density lipoprotein cholesterol (LDL‐C), fasting blood glucose (FPG), and asprosin, but a lower level of early diastolic movement speed (A) to diastolic movement velocity (E) (E/A). Asprosin was positively associated with waist circumference (WC), body mass index (BMI), creatinine, triglycerides (P 355.08 pg/mL [OR (95% CI) is 2.549 (1.275–5.095), P < 0.05] patients have a higher risk of left ventricular diastolic dysfunction. Conclusions Serum asprosin was positively associated with left ventricular diastolic dysfunction, and the risk of LVDD increased significantly with increased serum levels of asprosin.

Keywords

• Asprosin
• Left ventricular diastolic dysfunction
• Type 2 diabetes mellitus